中国实用外科杂志2017，Vol.37Issue(7)：751-754,4.DOI:10.19538/j.cjps.issn1005-2208.2017.07.11
晚期胰腺癌内科治疗策略
Progress of medical treatment of advanced pancreatic carcinoma
焦锋 1韩婷 1崔玖洁 1王理伟1
作者信息
- 1. 上海交通大学医学院附属仁济医院肿瘤科上海交通大学胰腺癌诊治中心,上海200127
- 折叠
摘要
Abstract
Most patients of pancreatic carcinoma are local advanced or distant metastasis occurred when diagnosed,and they don't have the chance to operate,with a poorer diagnosis. Positive internal medical treatment could prolong the overall survival time,and promote quality of life and improve the patients' life status. At present,the major therapy for advanced pancreatic cancer is gemcitabine-based combination treatment. For patients with a better ECOG performance status, the first line therapy could select FOLFIRINOX, gemcitabine combined nab-paclitaxel, gemcitabine combined fluorouracil,etc. For patients with worse ECOG performance status,single medication such as gemcitabine or fluorouracil. For patients with specific targeted genes,chemotherapy and targeted therapy could be combined,such as gemcitabine combined with erlotinib. The second line therapy is based on the first line therapy selection. Nanoliposomal irinotecan, gemcitabine, fluorouracil and irinotecan are now recommended. In the future,the treatment of pancreatic carcinoma should be based on the translational medicine,regarded the pancreatic cancer patients as a whole, focusing on microenvironment and immunological regulation. New treatments appliance and new targeted therapy should be explored,and clinical trials are strongly recommended. The final aim is to realize personal precision treatment instead of traditional diagnostic procedure.关键词
胰腺癌/内科治疗/靶向治疗/临床试验Key words
pancreatic carcinoma/internal medical treatment/targeted therapy/clinical trial分类
医药卫生引用本文复制引用
焦锋,韩婷,崔玖洁,王理伟..晚期胰腺癌内科治疗策略[J].中国实用外科杂志,2017,37(7):751-754,4.
